Note 1 - Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2021

Notes Tables

Debt Securities, Available-for-sale [Table Text Block]

	June 30, 2021
					Gross		Gross
	Amortized		Accrued		Unrealized		Unrealized		Estimated
	Cost		Interest		Gains		Losses		Fair Value
Obligations of U.S. Government and its agencies	$	7,174	$	—	$	1	$	—	$	7,175
Certificates of deposit		937		2		—		—		939
Total investments	$	8,111	$	2	$	1	$	—	$	8,114

	December 31, 2020
					Gross		Gross
	Amortized		Accrued		Unrealized		Unrealized			Estimated
	Cost		Interest		Gains		Losses			Fair Value
Obligations of U.S. Government and its agencies	$	24,986	$	14	$	3	$	(3	)	$	25,000
Certificates of deposit		3,225		11		3		—			3,239
Total investments	$	28,211	$	25	$	6	$	(3	)	$	28,239

Schedule of Receivables from Collaborations [Table Text Block]

	June 30, 2021
	Billed		Unbilled		Total
U.S. Department of Health and Human Services	$	—	$	6,381	$	6,381
Royalty receivables from partners		128		4		132
Total receivables	$	128	$	6,385	$	6,513

	December 31, 2020
	Billed		Unbilled		Total
U.S. Department of Health and Human Services	$	—	$	5,402	$	5,402
Royalty receivables from partners		2,816		25		2,841
Total receivables	$	2,816	$	5,427	$	8,243

Schedule of Inventory, Current [Table Text Block]

	June 30, 2021			December 31, 2020
Raw materials	$	4,990		$	206
Work-in-process		4,597			2,555
Finished goods		529			4,548
Total Inventory	$	10,116		$	7,309
Reserves		(270	)		(270	)
Total Inventory, net	$	9,846		$	7,039

Disaggregation of Revenue [Table Text Block]

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2021		2020		2021			2020
Product sales, net:
ORLADEYO	$	28,374	$	—	$	39,312		$	—
Peramivir		434		—		7,254			218
RAPIVAB		4,622		—		4,735			-
Total product sales, net		33,430		—		51,301			218
Royalty revenue		128		44		(769	)		1,989
Milestone revenue		15,000		—		15,000			—
Collaborative and other research and development revenues:
U.S. Department of Health and Human Services		1,401		2,545		3,486			4,152
Torii Pharmaceutical Co., Ltd.		—		282		—			1,335
Total collaborative and other research and development revenues		1,401		2,827		3,486			5,487
Total revenues	$	49,959	$	2,871	$	69,018		$	7,694